Strategy to avoid local recurrence in patients with locally advanced rectal cancer

BackgroundTo clarify the short- and long-term outcomes of radical surgery after neoadjuvant chemoradiotherapy (NCRT) with TS-1 and irinotecan, which enhances radiosensitivity, in patients with locally advanced rectal cancer.MethodsThe study group comprised 105 patients with locally advanced rectal cancer who received NCRT followed by radical surgery. NCRT consisted of pelvic radiotherapy (45Gy in 25 fractions over a period of 5weeks), S-1 (80mg/m(2)) given concurrently for 25days, and irinotecan (60mg/m(2)), given once a week as a continuous intravenous infusion. Radical surgery was performed 8weeks after treatment.ResultsA pathological complete response was confirmed in 23.8%. The 5-year recurrence-free survival rate was 79.3%, and the 5-year overall survival rate was 87.1%. Multivariate analysis showed that the following 4 variables were independent predictors of recurrence-free survival: Sex (male: p=0.0172), Pre-treatment tumor diameter (<40mm: p=0.0223), Histopathological treatment response (grade 0,1: p=0.0169), and ypN (ypN1: p=0.1995; ypN2: p=0.0007). Only ypN was an independent predictor of overall survival (ypN1: p=0.0009; ypN2: p=0.0012).ConclusionsOur treatment strategy combining TS-1 with irinotecan to increase radiosensitivity had a high response rate.